Celldex Therapeutics Inc (NASDAQ:CLDX) shares, rose in value on Wednesday, November 20, with price up by 5.68% to the previous day’s close as strong demand from buyers drove the stock to $26.40.
Actively observing the price movement in the last trading, the stock closed the session at $24.98, falling within a range of $25.0 and $26.78. The value of beta (5-year monthly) was 1.594. Referring to stock’s 52-week performance, its high was $53.18, and the low was $22.93. On the whole, CLDX has fluctuated by -8.21% over the past month.
With the market capitalization of Celldex Therapeutics Inc currently standing at about $1.75 billion, investors are eagerly awaiting this quarter’s results, scheduled for in December.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 1.31M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CLDX’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CLDX currently trading nearly 0.93% and -14.47% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 46.05, while the 7-day volatility ratio is showing 7.56% which for the 30-day chart, stands at 6.16%. Furthermore, Celldex Therapeutics Inc (CLDX)’s beta value is 1.57, and its average true range (ATR) is 1.70.
A comparison of Celldex Therapeutics Inc (CLDX) with its peers suggests the former has fared considerably weaker in the market. CLDX showed an intraday change of 5.68% in last session, and over the past year, it shrunk by -3.05%%.
Data on historical trading for Celldex Therapeutics Inc (NASDAQ:CLDX) indicates that the trading volumes over the past 10 days have averaged 1.04 and over the past 3 months, they’ve averaged 1.10 million. According to company’s latest data on outstanding shares, there are 66.34 million shares outstanding.
Nearly 2.50% of Celldex Therapeutics Inc’s shares belong to company insiders and institutional investors own 107.45% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 8.24 million shares as on 2024-10-31, resulting in a short ratio of 9.03. According to the data, the short interest in Celldex Therapeutics Inc (CLDX) stood at 1437.00 of shares outstanding as of 2024-10-31; the number of short shares registered in 2024-09-30 reached 8.31 million. The stock has fallen by -33.43% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CLDX stock heading into the next quarter.
